Effect of Probiotic Administration on Patients With Inflammatory Bowel Disease

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

May 30, 2024

Study Completion Date

June 30, 2024

Conditions
Inflammatory Bowel DiseasesQuality of LifeFood IntoleranceFlare UpUlcerative ColitisCrohn Disease
Interventions
DIETARY_SUPPLEMENT

Trilac

Trilac® is a dietary supplement developed by Surveal Pharma to support digestive health and overall well-being. This probiotic contains 4 strains of naturally-occurring bacteria including: Lactobacillus acidophilus, LA-5®, Bifidobacterium animalis, BB-12®, Streptococcus thermophiles, STY-31 and Lactobacillus delbrueckii subsp. Bulgaricus LBY-27 in concentration of 4.5 milliards CFU/capsule. Patients in the probiotic group will be instructed to take one tablet per day for a period of 8 weeks.

Trial Locations (1)

Unknown

RECRUITING

zahra Sadek, Beirut

All Listed Sponsors
lead

Lebanese University

OTHER